Adherex Technologies say early tests of its anti-cancer drug Exherin show “biological activity: in two Phase I patients.

Exherin is designed to disrupt the blood vessels of cancers. Results were well tolerated in all five tested doses, the company said. Two patients showed “biological activity,” Adherex said at an international cancer conference in New Orleans.

Although the data is only a “first step”, the company added that the initial findings might indicate “a useful approach in cancer therapy.”